154 F. Supp. 3d 1327
S.D. Fla.2016Background
- Plaintiff Maggie Tsavaris alleges long-term use of hormone replacement therapy (HRT) caused her estrogen/progesterone receptor–positive breast cancer; she took generic Activella manufactured by Breckenridge and never ingested Novo Nordisk’s brand Activella.
- Plaintiff sued multiple defendants alleging design defect, negligence, negligent misrepresentation against Breckenridge and brand liability and failure-to-warn against Novo Nordisk (and separate claims against Wyeth/Pfizer to be decided later).
- Breckenridge moved for judgment on the pleadings arguing federal preemption under the Hatch‑Waxman/FDCA framework (generic manufacturers cannot unilaterally change composition or labeling); Novo Nordisk moved to dismiss arguing no liability because plaintiff took only the generic product.
- Court applied Supreme Court precedents (Pliva v. Mensing, Mutual Pharm. Co. v. Bartlett, Wyeth v. Levine) and Eleventh Circuit precedent (Guarino) to evaluate preemption and brand‑name liability.
- Court held Breckenridge’s claims (defective design, negligence, negligent misrepresentation) are preempted because they effectively require redesign or stronger warnings that federal law forbids for generic manufacturers; court granted judgment for Breckenridge.
- Court dismissed Novo Nordisk with prejudice because under Florida law (as interpreted by the Eleventh Circuit) a brand‑name manufacturer is not liable to a consumer who ingested only the generic version.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether state tort claims against Breckenridge are preempted | Tsavaris: claims are not failure‑to‑warn and could be based on actions pre‑approval (safer design/testing) | Breckenridge: federal law forbids changing generic composition/label; state duties that require change are preempted | Preempted — judgment for Breckenridge granted |
| Whether defective‑design claim can proceed against a generic | Tsavaris: Breckenridge could have designed differently before FDA approval | Breckenridge: altering composition would create a new drug, violating Hatch‑Waxman/FDCA scheme | Preempted — design claim fails under Bartlett |
| Whether negligent and negligent‑misrepresentation claims avoid preemption by reframing as duties to test/study or not deceive | Tsavaris: these claims concern testing, research, and nondisclosure, not mere warnings | Breckenridge: those duties are subsumed by design/warning claims and no remedial action consistent with federal law exists | Preempted — negligence and negligent misrepresentation dismissed |
| Whether Novo Nordisk (brand) is liable though plaintiff ingested only generic | Tsavaris: brand can be liable because physicians rely on brand labeling and brand drafted the label | Novo Nordisk: Florida law (and Eleventh Circuit precedent) bars brand liability where only generic ingested | Dismissed with prejudice — Novo Nordisk not liable |
Key Cases Cited
- Pliva v. Mensing, 564 U.S. 604 (preemption of state failure‑to‑warn claims against generic manufacturers)
- Mutual Pharm. Co. v. Bartlett, 133 S. Ct. 2466 (U.S. 2013) (state design‑defect claims preempted when they would require a generic to change composition or labeling)
- Wyeth v. Levine, 555 U.S. 555 (brand manufacturer duty to ensure adequate warnings when it controls label)
- Guarino v. Wyeth, 719 F.3d 1245 (11th Cir. 2013) (applying Mensing to hold generic‑based failure‑to‑warn theories preempted and rejecting efforts to recast them)